OBJECTIVES: US dialysis centers typically dose ESA at every session (3x/wk), enabling frequent titrations. A once-monthly ESA is currently under FDA consideration. We recently demonstrated that more frequent Hb measurements and dose titrations are associated with higher ESA utilization. We developed an economic model to quantify the potential impact of switching from a 3x/wk ESA to one dosed monthly, due to fewer titrations and fewer Hb measurements, not considering other efficiencies (e.g., reduced administrations). METHODS: A cost-offset model estimated total ESA utilization and cost for monthly vs. 3x/wk dosing. Utilization inputs were derived from a retrospective study of prevalent (Ն 120 days), adult (Ͼ 18 years old) hemodialysis patients (nϭ78,730), dialyzing at a large dialysis organization between 01/01/09-12/31/10. Patients dosed 3x/wk experience 1.1 dose titrations and 2.9 Hb measurements on average per patient-month. Each additional monthly dose titration is associated with a 24.1% (95% CI: 21.5%-26.4%) increase in total ESA dose. Based on once-monthly ESA vs. 3x/wk ESA data (Provenzano et al., ASN 2011), we projected patients on a once-monthly ESA would experience 0.8 titrations and 1 Hb measurement per month, and projected savings-based reductions of mean titrations and tests. Price (derived from published sources), dose and clinical equivalence were assumed across ESAs. Model outcomes include incremental utilization and cost. RESULTS: The model predicts that switching patients to monthly ESA could result in a 7.95% (95% CI; 7.10%-8.73%) reduction in perpatient/month ESA utilization. This translates into savings of 5,322 (95% CI; 4,748 -5,839 U) ESA units/month/patient and $52.37 (95% CI; $46.72-$57.46) per-patient/ month. For an average facility (96 patients), we estimated ESA savings of 510,934 U/month and cost savings of $5,028/month. CONCLUSIONS: The model predicts that increasing the interval between ESA dose adjustments, based upon the FDA approval and administration of a once monthly ESA, could decrease ESA utilization.
OBJECTIVES: in the medical literature of co-occurrence of erectile dysfunction (ED) and benign prostatic hyperplasia (BPH) in men range from 20 to 80% depending on age, definition and severity of symptoms, and other patient characteristics studied. This study identifies the co-occurrence of these conditions, using healthcare insurance claims data, to provide payers with an estimate of these burdensome conditions. METHODS: Patients with ED and/or BPH were identified by diagnostic codes in the Thomson Reuters MarketScan® Database from January 1, 2007 to June 30, 2010 . Patients in the sample were categorized as having BPH, ED, or co-occurring BPH and ED, and were examined by age group (younger men aged 40-64 and older men 65 and above). RESULTS: Of 685,270 men who met eligibility criteria, 531,486 (77.6%) were younger men and 153,784 (22.4%) were older men. Overall, 416, 228 (60.7%) were diagnosed with ED (mean age 52.5), 336,432 (49.1%) were diagnosed with BPH (mean age 62.5), and 67,390 (9.8%) were diagnosed with both ED and BPH (mean age 60.3) in the study period. Among younger men, co-occurring ED and BPH accounted for 9.1% in men with ED or BPH, 13.4% in men with ED and 21.9% in men with BPH. Among older men, co-occurring ED and BPH accounted for 12.5% in men with ED or BPH, 34.3% in men with ED, and 16.5% in men with BPH. CONCLUSIONS: In this analysis, co-occurring ED and BPH varied in men by age. In younger men, co-occurring ED and BPH accounted for a greater percentage of those in the BPH cohort, whereas, in older men, co-occurrence accounted for a greater percentage of the ED cohort. This may be a reflection of coding in the claims data or may suggest that men may not seek treatment for both conditions or prioritize conditions differently as they age. 
PUK32 LOWER CASE MIX ADJUSTERS ARE ASSOCIATED WITH LOWER ERYTHROPOIESIS-STIMULATING AGENT (ESA) AND OTHER BUNDLED COSTS

OBJECTIVES:
To provide a cost-effectiveness analysis of treatments for moderate grade vesicoureteral reflux (VUR), an illness that accounts for an estimated $100 million in healthcare expenditures. Treatment options include antibiotics, nonsurgical endoscopic injection with dextranomer/hyaluronic acid, and surgical repair. METHODS: A systematic review using MEDLINE (search terms VUR, treatment, and cost) for 2006-2011. RESULTS: Dextranomer/hyaluronic acid injection is the more cost-effective option compared to ureteral reimplantation when success rates for dextranomer/hyaluronic acid injection are 58% per ureter for patients with unilateral reflux and 75% per ureter for bilateral reflux. If increasing grades of reflux require increasing volumes of dextranomer/hyaluronic acid, success rates of 73% for unilateral reflux and 94% for bilateral reflux represent the break-point for costeffectiveness. In models where dextranomer/hyaluronic acid injection is repeated if VUR does not resolve after initial injection, break-even success rates are 11% and 60% with unilateral reflux if success rates of initial injections were 70% and 55%, respectively. Break-even success rates for second dextranomer/hyaluronic acid injections are 29% and 77% per ureter with bilateral reflux, if success rates of initial injections are 70% and 55%, respectively. Based on 2011 epidemiologic estimates of 5580 children who are candidates for VUR treatments, dextranomer/hyaluronic acid injection endoscopic injections and clinical outcome success rates as reported in recent studies, potential annual savings with dextranomer/hyaluronic acid range from $1.5 million to $23 million. CONCLUSIONS: A nonsurgical approach is potentially associated with beneficial outcomes and cost-effectiveness. Longerterm studies are needed to refine the range of outcomes and downstream costs.
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VALIDATION OF ICD-9 CODES FOR THE IDENTIFICATION OF PATIENTS WITH STAGE 3-5 CHRONIC KIDNEY DISEASE IN ADMINISTRATIVE CLAIMS DATA
Grabner M, Chen Y, Palli SR, Quimbo RA HealthCore, Inc., Wilmington, DE, USA OBJECTIVES: Testing the validity of ICD-9-CM codes to identify diabetic patients with stage 3-5 chronic kidney disease (CKD) in claims data. METHODS: We conducted a cross-sectional study using claims from a large commercial health plan. Patients meeting the following criteria were included: 1) diagnosis of type 2 diabetes; 2) Ն12 months of continuous health plan eligibility; and 3) Ն2 non-zero serum creatinine lab values, at least 90 days apart, between January 1, 2004 and June 30, 2011. We identified 12 ICD-9-CM code groups potentially indicative of CKD stage 3-5 and validated them against a "gold standard", defined as two laboratory claims, at least 90 days apart, with an estimated glomerular filtration rate (eGFR) Ͻ60 mL/ min. eGFR was calculated using the CKD Epidemiology Collaboration equation and the Modification of Diet and Renal Disease (MDRD) equation. We calculated sensitivity, specificity, positive predictive value (PPV) and negative predictive value for the selected codes. Exact binomial 95% confidence intervals (CIs) were derived, and codes with a PPV whose lower CI bound was Ն 80% were considered valid. RESULTS: The study sample consisted of 383,970 patients. Approximately 16% of the sample (Nϭ61,052) had stage 3-5 CKD based on the "gold standard". ICD-9-CM codes for chronic renal failure, stage 3-5 (585.3-5), had a PPV of 84.2% (CI: 83.7% -85.7%). ICD-9-CM code 585.6, used for end-stage renal disease, had a PPV of 84.7% (CI: 83.6% -85.7%). ICD-9-CM code 285.21, used to describe anemia in CKD, had a PPV of 85.4% (CI: 84.6% -86.2%). For the remaining code groups, PPV ranged from 50% to 78%, with CIs of Ϯ 2 percentage points. Similar results were obtained when eGFR was calculated using the MDRD equation. CONCLUSIONS: This cross-sectional validation study suggests that diabetic patients with stage 3-5 CKD can be accurately identified in administrative claims data using selected ICD-9-CM codes.
PUK35 EQ-5D (UK AND THAI PREFERENCE WEIGHTS), SF-6D, AND VAS SCORES IN DIALYSIS THAI PATIENTS
tients and 62 peritoneal-dialysis patients at Siriraj hospital. Utility scores and the correlation coefficient with KDQOL-36 were calculated. Percentages of respondents with the ceiling and floor effects were compared for each of the different measurement tools. RESULTS: Patient samples had a mean age of 60.20Ϯ14.84 years. Mean duration of dialysis were 7.44Ϯ5.42 years for hemodialysis patients, and 1.82Ϯ1.22 years for peritoneal-dialysis patients. The mean SF-6D score (0.783Ϯ0.164) was significantly higher than EQ-5D (UK: 0.752Ϯ0.309, Thai: 0.691Ϯ0.314), and VAS (0.666Ϯ0.196) scores. Most of the kidney specific dimensions were better correlated with SF-6D than EQ-5D (UK and Thai preference weight) and VAS scores. Ceiling effects were observed in the EQ-5D concerning both UK and Thai preference weight, due to the fact that the EQ-5D differentiates less in the better health states, whereas the floor effects were not clearly observed in any instrument tools. CONCLUSIONS: SF-6D presented better correlation with kidney specific scales while the responsiveness of EQ-5D utility scores was poor. One explanation might be a ''ceiling effect'' of the EQ-5D. These findings implied that SF-6D utility scores could reflect HRQoL status of dialysis patients better than EQ-5D and VAS.
PUK36 USING BOOTSTRAP CONFIDENCE INTERVALS TO COMPARE RELATIVE VALIDITY COEFFICIENTS: AN EXAMPLE WITH PRO MEASURES OF CHRONIC KIDNEY DISEASE (CKD) IMPACT
Deng N, Ware J University of Massachusetts Medical School, Worcester, MA, USA OBJECTIVES: To evaluate bootstrap techniques in comparing the validity of PRO measures in discriminating among CKD patients and responding to longitudinal changes. METHODS: The Kidney Disease Impact Scale (KDIS), CKD-specific legacy (KDQOL Burden, Symptom, and Effect) and generic health (SF-12) scales were administrated to 453 patients and re-administered to 110 patients after three months. ANOVA-based relative validity (RV) coefficients were used to compare how well each scale discriminated between three clinically-defined groups ordered in terms of severity (Dialysis Ͼ Stage 3-5 Ͼ Transplant), and how responsive each scale was to changes over time for self-evaluated Better, Same and Worse groups. Bootstrap was used to construct confidence intervals (CIs) to determine whether the differences in RVs were significant in comparisons between each scale and the best legacy measure -KDQOL Burden. Sample size, number of bootstrap iterations, and type of CIs were varied to evaluate their impacts on CI using real and artificial data.
RESULTS:
The sample size played a substantial role. 300 people for 3 groups were suggested as the minimum number to make meaningful comparisons between RVs using CI. Number of bootstrap replications (100 to 10,000) did not show an obvious effect on bootstrap standard error, although 300 showed improvement over 100 on CI. The bias-corrected and accelerated (BCa) type of CI was preferred for correcting both bias and skewness in bootstrap distribution and for producing narrower CIs. Using 95% CI and 300 sample size, differences in RVs were non-significant in comparisons with KDQOL-Burden (RVϭ1) for the following scales: SF-12 PCS (RVϭ.6), PF (RVϭ.7), RP (RV ϭ .77), KDQOL-Effect (RVϭ.99), and KDIS (RVϭ1.13). CONCLUSIONS: Bootstrapping appears to be valuable in testing the significance of differences in the relative validity of these PRO measures from a statistical perspective. Samples of 100 per group compared and 300 bootstrap replications are recommended. Each article was reviewed by two independent investigators based on the reporting criteria recommended by the CONSORT statement. Exclusion criteria included non-randomized control studies, and studies not including intervention or control group. RESULTS: The study identified 129 published articles using explicit criteria on Medline search. A total of 73 randomized controlled trials met the inclusion criteria. Of 73 studies, 55 (75.34%) articles included the CONSORT diagram. A comprehensive depiction of the CON-SORT guidelines will be made and detail descriptions on the compliances will be presented by journal types during the presentation. CONCLUSIONS: Randomized controlled trials published in the top 10 general medicine journals and the top 5 infectious diseases journals in 2010 contain significant deficiencies in reporting the CONSORT flow chart. The clarity and the completeness of a study could be improved if the CONSORT statement is followed as prescribed. 
RESEARCH POSTER PRESENTATIONS -SESSION IV RESEARCH ON METHODS STUDIES RESEARCH ON METHODS -Clinical Outcomes Methods
PRM1 COMPLIANCE ON THE CONSOLIDATED STANDARDS OF REPORTING TRIALS (CONSORT) GUIDELINES IN RANDOMIZED CONTROLLED TRIALS
PRM2 NETWORK META-ANALYSIS OF INDIVIDUAL AND AGGREGATE LEVEL DATA
OBJECTIVES:
Network meta-analysis is often performed with aggregate level data (AD). A challenge with meta-regression models using AD is that the association between a patient level covariate and relative treatment effects of the compared interventions at the study level may not reflect the individual level effect-modification. In this paper, non-linear network meta-analysis models for combining individual patient data (IPD) and AD are presented to reduce bias and uncertainty of treatment effects in the presence of heterogeneity due to patient characteristics.
METHODS:
The first method uses the same model form for IPD and AD. With the second method, the model for AD is obtained by integrating an underlying IPD model over the joint within-study distribution of covariates. With a simple simulation study the two modeling approaches are compared. RESULTS: Having IPD for a subset of studies improves estimation of treatment effects with network metaanalysis in the presence of patient level heterogeneity and inconsistency. Of the two proposed non-linear models for combining IPD and AD, the second approach seems less affected by bias. Additional studies, however, are needed to assess the value of both methods. CONCLUSIONS: Overall, for network meta-analysis it is recommended to use IPD when available, rather than treating all studies as AD. 
PRM3 THE ENSEMBLE MINIMUM DATASET: A NEW INSTRUMENT TO EXPLORE HETEROGENEITY OF TREATMENT EFFECT
OBJECTIVES:
To develop an instrument that identifies patient groups likely to have differing responses to treatment, we tested candidate measures thought to discriminate differences among patients in 4 disease cohorts: type 2 diabetes (T2D), knee osteoarthritis (OA), ischemic heart disease (IHD) and heart failure (HF). METHODS: Eligible patients identified from claims data were sent a survey including 17 scales hypothesized to comprise 4 domains (health profile, personality, behavior, life context). Proxies for treatment response were patient-reported global impression of disease severity (PGIS), global impression of improvement (PGII), and administrative claims health care utilization (HCU). Variability (SD) and internal consistency (Cronbach's alpha) of the scales were examined, as was discriminant validity against strata of PGIS, PGII and HCU. Conceptual overlap, correlations among scales, and factor loading within and across domains were examined. Scales with desirable properties were included in the final instrument. Discriminant validity of proposed domains was analyzed by ANOVA adjusted for age and gender. Multiple regression models were used to assess the associations between the proposed domains and outcomes. RESULTS: A total of 723 T2D patients, 682 knee OA patients, 632 IHD patients, and 588 HF patients completed the survey. The initial instrument was refined to 7 scales across 3 domains. The health profile domain significantly discriminated 100% of the strata across disease cohorts (each PϽ0.001). Personality and behavior domains also discriminated strata well (75% and 50%, respectively). Alone, the health profile significantly discriminated strata across disease cohorts in multivariate analyses (each P Ͻ0.001). In models including all 3 domains, the health profile remained the most important contributor. CONCLUSIONS: The final ENSEMBLE MDS instrument discriminated among patients with varied diseases; the health profile provided much of the ability to discriminate. Further research is needed to assess the instrument's potential to predict health state changes due to trial interventions. 
PRM4 ENHANCING THE HEALTH ECONOMIC VALUE OF RETROSPECTIVE AND PROSPECTIVE REAL-WORLD STUDIES WITH PHARMACOGENOMIC TESTING: OPPORTUNITIES AND CHALLENGES ASSOCIATED WITH AN INTEGRATED PERSONALIZED MEDICINE APPROACH
OBJECTIVES:
A better understanding of a patient's genetic make-up through pharmacogenomic testing can help achieve improved and more predictable patient outcomes, often at equal or lower total treatment cost. Stakeholders including physicians, payers and patients alike can benefit from real-world data that identify, a priori, the sub-groups of patients for whom treatments are likely to be more cost-effective. METHODS: Retrospective and prospective case study designs within which pharmacogenomic testing has been integrated are presented. Design parameters are described and opportunities and challenges alongside strategies for resolution are delineated. RESULTS: As the genetic make-up of a patient does not change, pharmacogenomic testing can be done at any point in time and paired with historical and/or newly collected patient level data. Retrospective studies are highly efficient as they do not require costly longitudinal follow-up, whereas prospective studies including registries offer the opportunity to augment pharmacogenomic and other study data with patient and physician reported outcomes not otherwise available in the medical chart. Main challenges associated with either approach include optimizing the patient informed consent process, streamlining the logistics associated with pharmacogenomic testing and storage in the usual A159 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 -A 2 5 6
